2015 Annual Meeting | 3HC.009 - Neuro-oncology: Primary Brain Tumors

Date Monday 04/20/15

Time 08:00 AM - 12:00 PM Add To Calendar

Session Format This program will be presented both in-person and online

On Demand This program is not expected to be available in the meeting's On Demand product.

Event Type Half-Day Course

Director(s) Erin M. Dunbar, MD

Topic(s)

Learning Objectives Participants should have sufficient knowledge to incorporate a systemized approach to the treatment of primary brain tumors within their practices; utilize highest level evidence and treatment guidelines; support superior outcomes and clinical trial enrollment; and optimize patient/physician satisfaction.

CME Available 3.75 CME credits

Recommended Audience Trainee, General Neurologist, Specialist Neurologist, Non-neurologist

Teaching Styles Case-based, Didactic, Interactive, Audience Participation

Event Timeline
08:00 AM - 08:05 AM		Introduction Erin M. Dunbar, MD
08:05 AM - 08:40 AM		Practical Tumor-directed and Symptom-directed Approaches to Primary Brain Tumors Erin M. Dunbar, MD
08:40 AM - 09:15 AM		Benign Brain Tumors: In Good Times and in Bad Scott R. Plotkin, MD, PhD, FAAN
09:15 AM - 09:25 AM		Break
09:25 AM - 10:00 AM		Low-grade Gliomas: Not Just A Neurosurgeon's Dilemma Anymore Michael A. Vogelbaum, MD, PhD, FACS
10:00 AM - 10:35 AM		High-grade Gliomas: Progress Taming the Beast Jaishri Blakeley, MD, FAAN
10:35 AM - 11:15 AM		Questions and Answers
11:15 AM - 12:00 PM		Tumor Board: Cases Highlighting Common Dilemmas and Audience Questions

Faculty Disclosures
Erin M. Dunbar, MD	Dr. Dunbar has nothing to disclose.
Jaishri Blakeley, MD, FAAN	Dr. Blakeley has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Springworks Therapeutics.
Scott R. Plotkin, MD, PhD, FAAN	Dr. Plotkin has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for NFlection Therapeutics. Dr. Plotkin has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Akouos. Dr. Plotkin has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for SonALAsense. Dr. Plotkin has stock in NFlection Therapeutics. Dr. Plotkin has stock in NF2 Therapeutics. Dr. Plotkin has stock in SonALAsense. Dr. Plotkin has received research support from Children's Tumor Foundation. Dr. Plotkin has received research support from Department of Defense. Dr. Plotkin has received research support from National Institutes of Health. Dr. Plotkin has received intellectual property interests from a discovery or technology relating to health care.
Michael A. Vogelbaum, MD, PhD, FACS	No disclosure on file

��ɫ��

��ɫ��